||
《科学》杂志获得的一份未发表的病例报告中描述的临床试验死亡病例,是第二次被认为与一种名为lecanemab的抗体有关。https://blog.sciencenet.cn/blog-41174-1365633.html
http://www.pubmedplus.cn/P/SearchQuickResult?wd=d328386b-5098-402d-a6d9-76953e1abb5f
01. | 无法确认 | 5 篇 | 14.286% |
02. | 2022 | 12 篇 | 34.286% |
03. | 2021 | 10 篇 | 28.571% |
04. | 2020 | 4 篇 | 11.429% |
05. | 2018 | 2 篇 | 5.714% |
06. | 2016 | 1 篇 | 2.857% |
01. | alzheimers res ther | 5 篇 | 14.286% |
02. | rev neurol (paris) | 3 篇 | 8.571% |
03. | j prev alzheimers dis | 2 篇 | 5.714% |
04. | neurol ther | 2 篇 | 5.714% |
05. | transl neurodegener | 2 篇 | 5.714% |
06. | alzheimers dement | 1 篇 | 2.857% |
07. | alzheimers dement (n y) | 1 篇 | 2.857% |
08. | cell mol life sci | 1 篇 | 2.857% |
09. | cpt pharmacometrics syst pharmacol | 1 篇 | 2.857% |
10. | curr neurol neurosci rep | 1 篇 | 2.857% |
01. | 美国 | 18 篇 | 51.429% |
02. | 瑞典 | 7 篇 | 20.000% |
03. | 法国 | 5 篇 | 14.286% |
04. | 英国 | 4 篇 | 11.429% |
05. | 日本 | 2 篇 | 5.714% |
06. | 中国 | 1 篇 | 2.857% |
07. | 澳大利亚 | 1 篇 | 2.857% |
08. | 巴西 | 1 篇 | 2.857% |
09. | 加拿大 | 1 篇 | 2.857% |
10. | 意大利 | 1 篇 | 2.857% |
01. | 中国长春 | 1 篇 | 2.857% |
02. | 中国深圳 | 1 篇 | 2.857% |
01. | Alzheimer Disease | 22 篇 | 62.857% |
02. | Humans | 22 篇 | 62.857% |
03. | Amyloid beta-Peptides | 16 篇 | 45.714% |
04. | Antibodies, Monoclonal, Humanized | 11 篇 | 31.429% |
05. | Antibodies, Monoclonal | 10 篇 | 28.571% |
06. | Amyloid | 9 篇 | 25.714% |
07. | Brain | 7 篇 | 20.000% |
08. | Animals | 4 篇 | 11.429% |
09. | Immunotherapy | 4 篇 | 11.429% |
10. | Plaque, Amyloid | 4 篇 | 11.429% |
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-9-27 09:24
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社